Chicago, IL - Results of two trials of tolvaptan (Otsuka America Pharmaceutical), a novel oral vasopressin V2-receptor antagonist, show that treatment effectively increased serum sodium concentrations ...

As a general rule, the treatment of hyponatremia should be directed at the primary underlying disorder because such treatment might, in itself, correct the electrolyte imbalance. Thiazide diuretics ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s Cardiovascular and Renal Drugs Advisory Committee today did not recommend approval of lixivaptan for ...

These agents compete with AVP for the vasopressin type 2-receptor and block the effects of AVP to increase free water absorption. Since these agents lead to increases in free water excretion with ...

CHICAGO, Oct. 27 ReachMD XM 157 announces a new "MedicalIndustry Feature of the Week" highlighting a vasopressin receptor antagonistand its effects on management of euvolemic and hypervolemic ...

VAPRISOL (conivaptan) 20mg/ampule by Astellas Pharma Vaprisol (conivaptan HCl, from Astellas Pharma) Premixed injection, an arginine vasopressin (AVP) receptor antagonist, is available for the ...

Hyponatremia is a condition wherein the concentration of sodium in the blood is low. The normal level of sodium in serum is between 135-145 mEq/L. In hyponatremia, the blood sodium levels fall below ...

VAPRISOL (conivaptan) 20mg/ampule by Astellas Pharma A premixed formulation of Vaprisol (conivaptan HCl injection, from Astellas) has been approved for the treatment of hospitalized patients with ...

hospital patient_TS_512098822 Study characterizes death risk associated with hyponatremia in patients with lymphoma and breast, lung, and colorectal cancer. Hyponatremia develops frequently and ...

Hyponatremia refers to an abnormally low level of the electrolyte sodium (salt) in the blood. Sodium is an electrolyte that helps regulate the amount of water within and around cells in the body.

The FDA has approved an intravenous drug for hospital patients suffering from potentially life-threateningly low sodium levels, the drug's manufacturer said Friday. Astellas Pharma US Inc. said it ...